Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Argenx to $533 from $478 and keeps an Outperform rating on the shares. Looking ahead to the company’s R&D day next Tuesday, the firm says it doesn’t expect any surprise updates that’ll necessarily move the stock much on that day, but “that doesn’t mean the event isn’t very interesting/important for the company.” Moving on from here, the story isn’t just about the CIDP launch, which Evercore calls “more of a 2025 story,” but also how the rest of the pipeline should be contributing to the valuation, says the analyst, who has refreshed the firm’s model.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Lexeo Therapeutics appoints Tim Van Hauwermeiren to board of directors
- Biotech Alert: Searches spiking for these stocks today
- Argenx price target raised to $490 from $448 at H.C. Wainwright
- Argenx Unveils Promising Autoimmune Therapy Data
- argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting